IRLAB Therapeutics is swiftly progressing with the Phase I trial for IRL757, with the first participant recently dosed following regulatory approval earlier this month. IRL757 is being developed for the treatment of apathy, a common symptom in neurological conditions such as Parkinson's disease (PD) and Alzheimer's disease (AD), but with limited treatment options. The Phase I study will include two parts - with single and multiple ascending doses - which IRLAB plans to complete within CY24. The clinical programme has been de-risked in terms of funding to proof-of-concept (PoC) with backing from the MJFF and MSRD. We update our valuation to reflect the potential contribution from IRL757 (with a conservative peak penetration of 5% and a probability of success of 7.5%). We also note IRLAB has drawn down the remaining SEK25m from the SEK50m debt facility, which we were already reflecting in our model. With these updates, our valuation rises to SEK4.56bn or SEK87.9/share, from SEK4.25bn or SEK81.9/share previously.Den vollständigen Artikel lesen ...
IRLAB has confirmed that clinical candidate IRL757, which has been designed to address apathy in patients with neurodegenerative conditions, will proceed to the next stages of clinical development.... ► Artikel lesen
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY. GOTHENBURG, SE / ACCESS Newswire / March 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company... ► Artikel lesen
IRLAB Therapeutics has announced the publication of preclinical data on mesdopetam in the prestigious peer-reviewed journal, European Journal of Neuroscience. The research provided insights into the... ► Artikel lesen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.